http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107206101-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6805 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6805 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2015-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107206101-B |
| titleOfInvention | Quaternary ammonium compounds and their antibody-drug conjugates |
| abstract | The present application relates to an antibody-drug conjugate represented by formula (I): Ab—(L—D) p , Ab is an antibody; p is 1—8; L—D is a chemical moiety represented by the formula:—Str —(Pep)—Sp—D; Str is a stretch base unit covalently linked to Ab; Pep is a linking group; D is an antitumor agent represented by the following left formula, wherein R 20 and R 30 are each independently C 1 ‑ C6 alkyl, and R10 is a non-hydrogen substituent; or R30 is C1 -C6 alkyl , and R10 and R20 together with N form a substituted C3 - C7 heterocycloalkyl ring; or R 30 is absent, and R 10 and R 20 together with N form a substituted heteroaryl ring; Sp—D is the spacer moiety of the formula below. The application also relates to methods of treating cancer, the use of the antibody-drug conjugate of formula (I) in therapy and the use of the antibody-drug conjugate of formula (I) in the manufacture of a medicament for the treatment of cancer. The present application also relates to methods of preparing the antibody-drug conjugates of formula (I). |
| priorityDate | 2014-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1031.